Bacteriophage Therapy Market to Surpass US$ 1,651.8 Mn by 2030 - Coherent Market Insights

According to Coherent Market Insights, The global bacteriophage therapy market is estimated to be valued at US$ 1,280.9 million in 2023 and is expected to exhibit a CAGR of 3.7% during the forecast period (2023-2030).
Bacteriophage therapy involves the use of bacteriophages or bacterial viruses to treat bacterial infections. It utilizes the lytic cycle of phages to kill bacterial pathogens effectively without harming human cells. This alternative approach is gaining prominence due to the growing antimicrobial resistance of bacteria to conventional antibiotics.

Market Dynamics:

The global bacteriophage therapy market is expected to witness significant growth over the forecast period, owing to the rising prevalence of antimicrobial resistance worldwide. According to the World Health Organization, antimicrobial resistance is rising globally due to overuse and misuse of antibiotics, threatening the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses and fungi. This has prompted research into developing effective alternatives like bacteriophage therapy. Additionally, various regulatory approvals and clinical trials for bacteriophage therapy products are also fueling market growth. In 2021, the US Food and Drug Administration granted several bacteriophage therapy products as Generally Recognized as Safe (GRAS).

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2752

Market Driver:

The overuse and misuse of antibiotics has led to a rise in antibiotic-resistant strains of bacteria. The World Health Organization has highlighted antibiotic resistance as one of the biggest threats to global health today. More people are now aware of this growing crisis and looking for alternative treatment methods. Bacteriophage therapy is gaining attention as a potential solution since phages are bacterial viruses that can kill only specific bacterial strains without harming human cells. As antibiotic efficacy decreases, demand is increasing for alternatives like phage therapy that can effectively treat antibiotic-resistant infections.

Market Restraint:

While phage therapy shows promise, the lack of rigorous clinical trials is a major restrain for the market. Phages are living organisms and each works against a limited range of bacterial strains, so standardizing treatments is challenging. Regulators require extensive data from well-controlled human studies before approving new therapies. However, conducting large-scale clinical trials on phages is difficult due to their specific nature. Variables like phage dose, timing of administration, and phage-bacteria interactions are hard to control. Researchers also face difficulties in securing funding for long-term trials and lack guidelines for trial design. Until robust clinical evidence becomes available, regulatory approval and adoption of phage therapy will remain limited.

Competitive Landscape

In the segment specifically devoted to leading companies in the Bacteriophage Therapy Market of the market analysis document, our researchers provide a summary of the financial statements of all the major companies, covering their noteworthy developments, product benchmarking, and SWOT analysis. The corporate profile copy also includes financial information and a business summary. The businesses in this area can be customized to match the unique needs of the client.

Some of the Top Players in Bacteriophage Therapy Market:

Armata Pharmaceuticals, Inc., Eliava Biopreparations Ltd., Pherecydes Pharma, Intralytix, Inc., Phagelux, Inc., Nextbiotics, InnoPhage, Ltd, Locus Biosciences, Inc., TechnoPhage, Eligo Bioscience SA, Phagomed Biopharma GmbH., PhagePro, Inc., Adaptive Phage Therapeutics, Enbiotix, Inc., Intodeworld, Inc., BiomX Ltd., Phi Therapeutics, Fixed-phage Ltd., Micreos BV, ContraFect Corporation, OPTIPHARM Co., Ltd.

Bacteriophage Therapy Market Detailed Segmentation:

Global Bacteriophage Therapy Market, By Targeted Bacteria:
Escherichia coli
Staphylococcus aureus
Streptococcus
Pseudomonas aeruginosa
Salmonella
Others

Global Bacteriophage Therapy Market, By Disease Indication:
Urinary Tract Infections
Chronic Otitis
Dental Extraction
Chronic Ulcerative Colitis
Bone Infection
Wound and Skin Infections
Cystic Fibrosis
Others

Global Bacteriophage Therapy Market, By Route of Administration:
Oral
Topical
Parenteral

Global Bacteriophage Therapy Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Get a Discount on the purchase of this report @ https://www.coherentmarketinsights.com/insight/buy-now/2752

Regional Analysis -

North America (U.S., Canada, Mexico)
Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
Latin America (Colombia, Brazil, Argentina, Rest of Latin America)
Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Market Opportunity:

Since different phages infect specific bacteria, this offers potential for personalized medicine. Treatment could involve testing a patient's infection to identify the causative bacteria, then selecting the most suitable phages. Phage cocktails may even be customized for each individual. This personalized approach is a major contrast to conventional antibiotics which have broad effects. As genetics and diagnostics advance, it may become possible to rapidly sequence bacterial genomes and select optimum phage combinations on a case-by-case basis. Such customizable therapy promises to improve outcomes for patients with multi-drug resistant infections not treatable by other means.

Market Trend:

The future outlook for the bacteriophage therapy market is promising. Growing antibiotic resistance has incentivized increased R&D funding and investments in phage-based alternatives. More companies recognize the long-term commercial potential and are developing phage-based products, particularly for resistant bacterial threats like C. difficile and Pseudomonas aeruginosa. Research focuses on areas like engineering phages with improved efficacy, stability and safety profiles. Regulatory guidelines are also evolving to facilitate clinical research. If ongoing challenges around trial standardization can be addressed, phage therapy may finally emerge as a mainstream treatment option within the next decade - supported by ongoing market trends of rising resistance and efforts towards innovative solutions.

Reasons to Purchase this Report:

✔ Regional report analysis highlighting the consumption of products/services in a region also shows the factors that influence the market in each region.
✔ Reports provide opportunities and threats faced by suppliers in the Bacteriophage Therapy industry around the world.
✔ The report shows regions and sectors with the fastest growth potential.
✔ A competitive environment that includes market rankings of major companies, along with new product launches, partnerships, business expansions, and acquisitions.
✔ The report provides an extensive corporate profile consisting of company overviews, company insights, product benchmarks, and SWOT analysis for key market participants.
✔ This report provides the industry's current and future market outlook on the recent development, growth opportunities, drivers, challenges, and two regional constraints emerging in advanced regions.

Buy-Now @ https://www.coherentmarketinsights.com/insight/buy-now/2752

📌Contact Us:
Mr. Shah
Coherent Market Insights Pvt. Ltd,
📞Phone: U.S.: +1-206-701-6702
📞U.K.: +44-020-8133-4027
📞JAPAN: +81-50-5539-1737
📞INDIA: +91-848-285-0837
✉ Email: sales@coherentmarketinsights.com

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

This release was published on openPR.